Ian E. Krop
Advertisement
Articles by Ian E. Krop
44 Results From the Phase 1/2 Study of Patritumab Deruxtecan (HER3-DXd), a HER3-Directed Antibody-Drug Conjugate (ADC), in Patients (pts) With HER3- Expressing Metastatic Breast Cancer (MBC)
ByIan E. Krop,Norikazu Masuda,Toru Mukohara,Shunji Takahashi,Takahiro Nakayama,Kenichi Inoue,Hiroji Iwata,Tatsuya Toyama,Yutaka Yamamoto,Damien Hansra,Masato Takahashi,Akihiko Osaki,Kumiko Koyama,Tatsuya Inoue,Takatoshi Yonekura,Joseph Mostillo,Shoichi Ohwada,Yoshimi Tanaka,David Sternberg,Kan Yonemori
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
3
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
4
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
5
